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The synthesis of two new -aminophosphonic acids, namely 
(2S*,3aS*,7aS*)- and (2R*,3aS*,7aS*)-octahydroindole-2-
phosphonic acids, is described. They are analogues of 
phosphoproline bearing a cyclohexane ring fused to the pyrrolidine 
moiety. The ring junction presents a cis stereochemistry in both 
cases, whereas the two compounds differ in the relative orientation  
of the cyclohexane and phosphonate moieties. The two amino 
acids have been prepared from a common starting material 
following stereodivergent routes that provide the desired 
stereoisomer with complete stereocontrol. The relative 
configuration of the compounds synthesised has been confirmed 
by X-ray diffraction analysis. 
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Introduction 
-Aminophosphonic acids are surrogates of -amino acids in 
which the planar carboxylic acid (CO2H) has been replaced by a 
sterically more demanding tetrahedral phosphonic acid 
[P(O)(OH)2]. This replacement brings about important differences 
not only in molecular shape but also in acidity and other properties. 
-Aminophosphonic acids are currently attracting a great deal of 
interest in medicinal chemistry, as well as in agrochemistry, due to 
their outstanding biological and pharmacological properties.[1,2] 
Thus, some of these compounds or their derivatives, including 
short peptides that incorporate them, find application as 
antibacterial, antiviral, and antifungal agents or as insecticides and 
herbicides. Others show promising anticancer activity or have 
proven effective in the treatment of osteoporosis. 
The relevant properties exhibited by -aminophosphonic acids 
have stimulated the development of synthetic methods for these 
compounds.[1,2a,3] Much effort has been devoted in the last decades 
to the preparation of the phosphonic analogues of the 20 
proteinogenic amino acids[4] and, as a result, procedures for the 
synthesis of most of them are currently available. Once this goal 
was achieved, the present challenge faces the search for new 
structures, other than those analogous of the coded -amino acids. 
In this context, the wide variety of non-coded -amino acids 
synthesised in the last years by introduction of different types of 
modifications on the coded residues provides an invaluable source 
of inspiration. In particular, those non-proteinogenic -amino acids 
that have already shown exceptional properties are ideal candidates 
to serve as models for the construction of new -aminophosphonic 
acids. 
Among such highly relevant non-coded -amino acids is 
octahydroindole-2-carboxylic acid (known in the abbreviated form 
as Oic, Figure 1). Oic is a proline analogue bearing a cyclohexane 
ring fused to the pyrrolidine cycle. Due to synthetic limitations, 
only the (2S,3aS,7aS) stereoisomer, characterized by a cis ring 
fusion and usually referred to as L-Oic (Figure 1), has been 
profusely investigated. This amino acid has allowed the 
development of highly potent, long-lasting peptides or peptide-
related molecules that find application as antiinflammatory, 
antiallergic, and analgesic agents, in the treatment of 
neurodegenerative diseases, and in the prevention of cardiovascular 
disorders, among others.[5,6] Some of these L-Oic-containing 
compounds are already commercial (as the dipeptide Perindopril, 
one of the top antihypertensive drugs in the market[6g,i]) while 
others have entered clinical evaluation. Synthetic methods for the 
preparation of the remaining Oic stereoisomers are currently 
available, with some of them having been developed in our 
laboratories.[5] 
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Figure 1. a) Structure of the proline analogue octahydroindole-2-carboxylic 
acid (Oic) (the positions of the chiral carbons are indicated). The most 
widely studied stereoisomer of Oic (L-Oic) is shown. b) Structure of the 
phosphonic surrogates of Oic whose synthesis is described in the present 
work. 
The high value of L-Oic, together with our experience in the 
synthesis of different Oic stereoisomers and our interest in 
aminophosphonic acids, prompted us to undertake the preparation 
of two phosphonic surrogates of Oic, namely those exhibiting a cis 
ring junction and either a cis or a trans stereochemistry between 
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the six-membered cycle and the phosphonic group, that is, 
(2R*,3aS*,7aS*)- and (2S*,3aS*,7aS*)-octahydroindole-2-
phosphonic acids, respectively (Figure 1). 
Results and Discussion 
The target compounds differ in the stereochemistry at the  
carbon while share a cis stereochemistry at the ring junction. Our 
experience[5] in the synthesis of Oic derivatives made us consider 
hydrogenation of an unsaturated precursor of the octahydroindole 
system as the most convenient transformation to ensure a cis ring 
fusion. On the other hand, we reasoned that a lactam system could 
provide the appropriate scaffold to create the desired -
aminophosphonate functionality (Scheme 1). This consideration 
was based on two synthetic precedents described in the literature: 
a) the well-known reduction of the carbonyl group at the C5 
position of N-acyl pyroglutamic acid (5-oxoproline) derivatives to 
give the corresponding hemiaminal and further transformation into 
an aminal and then into an N-acyliminium ion, which undergoes 
the addition of nucleophiles to provide access to 5-substituted 
prolines;[7] b) the reaction of trialkyl phosphites with N-
acyliminium ions derived from -methoxycarbamates, first 
reported by Shono.[8]  
N
COR
O
N
COR
OR'
N
COR
+
N
H
P(OH)2
O
 
Scheme 1. Use of a lactam moiety as a precursor of an -aminophosphonic 
acid. 
These considerations made us select commercially available 2-
indolinone (1, Scheme 2) as the starting material for the synthesis 
of the target compounds. This substrate bears a -lactam 
appropriate for the generation of the -aminophosphonate 
functionality. Simultaneously, it contains the desired bicyclic 
system exhibiting a double bond at the ring junction, which ensures 
a cis fusion upon hydrogenation. Most importantly, the sequence in 
which these key transformations are performed is crucial to define 
the stereochemistry of the final product, as explained in the 
following. 
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Scheme 2. Structure of 2-indolinone (also named 2-oxindole, 1), selected as 
a common precursor of the target aminophosphonic acids. 
Firstly, we undertook the preparation of the derivative exhibiting 
a trans relative disposition between the phosphonic group and the 
six-membered cycle, that is, (2S*,3aS*,7aS*)-octahydroindole-2-
phosphonic acid. The first step in the synthesis involved 
hydrogenation of the aromatic ring in 1 (Scheme 3). The process 
was completed smoothly under an atmospheric pressure of 
hydrogen gas using platinum(IV) oxide as the catalyst and 
provided cis-octahydroindol-2-one (2) in quantitative yield. Such 
reaction conditions were selected on the basis of our previous 
experience in the preparation of Oic derivatives. We had 
observed[9] that PtO2 allows the hydrogenation of indoline 
derivatives to proceed under mild reaction conditions whereas 
other catalytic systems based on palladium or rhodium have been 
reported[5,10] to require high pressures of hydrogen gas. 
Compound 2 exhibits the desired cis stereochemistry at the ring 
junction and bears a -lactam functionality. Introduction of an acyl 
group on the nitrogen atom is a prerequisite for further 
transformation into an -aminophosphonate as outlined in Scheme 
1. An acyl substituent of the carbamate type, namely the tert-
butoxycarbonyl (Boc) group, was selected for this purpose since 
subsequent deprotection to generate the amino function can be 
accomplished under mild conditions. Treatment of 2 with di- tert-
butyl dicarbonate (Boc2O) in the presence of a catalytic amount of 
4-(dimethylamino)pyridine (DMAP) afforded the desired N-Boc 
protected derivative 3 in good yield (Scheme 3). This compound  
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Scheme 3. Synthesis of (2S*,3aS*,7aS*)-octahydroindole-2-phosphonic acid. 
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was made react with di-iso-butylaluminum hydride (DIBAL-H) to 
yield the unstable hemiaminal 4, which was not isolated and was 
treated immediately with methanol and catalytic pyridinium p-
toluenesulfonate (PPTS) to provide the methoxyaminal 5. 
Subsequent reaction with trimethyl phosphite in the presence of 
boron trifluoride etherate[8] led to the formation of 7 via the 
intermediate N-acyliminium 6. Notably enough, the desired 
dimethyl N-Boc-octahydroindole-2-phosphonate (7) was obtained 
as a single stereoisomer, with no trace of the epimer at the  
carbon being detected by either 1H or 31P NMR analysis of the 
crude product. The isolated compound presumably exhibits a 
(2S*,3aS*,7aS*) relative configuration since the nucleophilic attack 
of trimethyl phosphite on 6 most probably occurs from the less 
hindered face of the molecule, that is, opposite to the six-
membered cycle. X-ray diffraction analysis of single crystals of 7 
(Figure 2) confirmed the expected (2S*,3aS*,7aS*) stereochemistry, 
characterized by a trans arrangement of the cyclohexane and 
phosphonate moieties. 
 
Figure 2. X-ray crystal structure of 7, exhibiting a (2S*,3aS*,7aS*) relative 
stereochemistry (only one enantiomer is shown). All hydrogen atoms, 
except those attached to chiral carbons, have been omitted for clarity. 
Removal of the protecting groups to obtain the free amino acid 
(8) was accomplished by treatment with a 33% solution of 
hydrogen bromide in acetic acid (Scheme 3). Additionally, 
selective deprotection of the amino function was attempted to 
generate the aminophosphonate 9, which may be of use for further 
derivatization. Unfortunately, the phosphonate ester proved not 
completely stable under the reaction conditions typically used to 
remove the Boc group. Thus, treatment of 7 with either a 3N 
solution of hydrogen chloride in ethyl acetate or a 4:6 mixture of 
trifluoroacetic acid (TFA) and dichloromethane resulted in partial 
deprotection of the dimethyl phosphonate and, as a consequence, a 
mixture of products (including the ester, the hemiester and the free 
acid) was isolated. Selective cleavage of the N-Boc protecting 
group in 7 was finally achieved with a highly diluted solution of 
TFA in dichloromethane (0.5N), as previously reported by Ricci et 
al.[11] This procedure afforded the -aminophosphonate 9 in 
excellent yield (Scheme 3).  
The synthesis of the epimeric derivative, (2R*,3aS*,7aS*)-
octahydroindole-2-phosphonic acid, was next addressed. In this 
case, the introduction of the phosphonate group was envisaged 
prior to the reduction of the benzene ring to favour the desired cis 
relative disposition between the cyclohexane and phosphonate 
moieties. Accordingly, the first step in the route involved the 
introduction of a Boc protecting group in 2-indolinone (1). This 
process was not straightforward because of the nitrogen atom being 
flanked by an aromatic ring and a carbonyl group. As seen in 
Scheme 3, the presence of a carbonyl moiety contiguous to the 
nitrogen atom in 2 does not hamper reaction with di-tert-butyl 
dicarbonate provided that catalytic DMAP is present. We have also 
observed[12] that the same conditions are effective for the N-Boc 
protection of the amino group in indoline-derived systems, where it 
is adjacent to a benzene ring. However, both situations coexist in 2-
indolinone (1), which presents, in addition, a highly reactive 
position towards electrophiles. It was, therefore, not unexpected 
that the conditions used for the N-Boc protection of 2 failed when 
applied to 1. No reaction was observed when tetrahydrofuran 
(THF) was used as a solvent, whereas acetonitrile afforded a 
complex mixture of compounds, including 10 and several products 
arising from the single or multiple acylation at the 1 (N), 2 (O-
acylation), or 3 positions of the five-membered cycle. Similar 
products have been reported[13] to be formed when triethylamine is 
added to the THF/DMAP system. Fortunately, the conditions 
developed for the carbamoylation of 2-indolinones based on the 
use of sodium carbonate in THF[14] proved successful and allowed 
the isolation of 10 in good yield (Scheme 4). 
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Scheme 4. Synthesis of (2R*,3aS*,7aS*)-octahydroindole-2-phosphonic acid. 
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The introduction of a phosphonate group in 10 was next 
attempted via the formation of the intermediate hemiaminal, aminal, 
and iminium derivatives, as reported above for the trans compound 
(Scheme 3). However, in this case, reduction of 10 with DIBAL-H 
did not afford the expected hemiaminal 11 (Scheme 4). Instead, N-
Boc-indole was formed, presumably due to a straightforward 
aromatization of the reduced compound. In contrast, when lithium 
triethylborohydride (Super-Hydride®) was used as the reducing 
agent, the desired hemiaminal (11) was obtained (Scheme 4). 
Difficulties were also encountered when this compound was made 
react with methanol to form the methoxyaminal. Again, N-Boc-
indole was isolated instead of the expected O-methylated product.  
These difficulties prompted us to consider the direct 
transformation of the hemiaminal 11 into the iminium functionality 
without formation of the intermediate aminal derivative, as 
reported by some authors.[15] On this basis, compound 11 was 
directly treated with boron trifluoride etherate and trimethyl 
phosphite to afford the N-Boc-indoline-2-phosphonate 13 (Scheme 
4). Although a significant amount of N-Boc-indole was also 
formed in this process, the desired compound was isolated in 30% 
overall yield from 10.  
The hydrogenation of the aromatic ring in 13 was carried out 
using PtO2 as a catalyst under the conditions commented above and 
afforded the octahydroindole derivative quantitatively. Notably 
enough, this hydrogenation process provided exclusively dimethyl 
(2R*,3aS*,7aS*)-octahydroindole-2-phosphonate (14), with no 
trace of the (2S*,3aS*,7aS*) epimer (7) being observed in the 1H 
and 31P NMR spectra. Hydrogenation of the benzene ring in 13 
takes place from the less hindered face, i.e. that opposite to where 
the phosphonate group lies. As a consequence, the reduced system 
exhibits the cyclohexane moiety cis to the phosphonate substituent, 
as confirmed by X-ray diffraction analysis of 14 (Figure 3). The 
complete stereoselectivity of the process is highly remarkable and 
superior to that observed when the homologous carboxylic acid 
derivative was hydrogenated under similar conditions.[5,9] In the 
latter case, a 90:10 mixture of epimers was obtained, with 
predominance of the cis derivative. The higher selectivity observed 
in the present work may be attributed to the larger steric hindrance 
associated to the dimethyl phosphonate group relative to the 
carboxylate moiety. 
 
Figure 3. X-ray crystal structure of 14, exhibiting a (2R*,3aS*,7aS*) 
relative stereochemistry (only one enantiomer is shown). All hydrogen 
atoms, except those attached to chiral carbons, have been omitted for clarity. 
Finally, acidic treatment of 14 under similar conditions to those 
described for the trans derivative allowed the isolation of the 
dimethyl aminophosphonate 16 and the free amino acid 15 in 
excellent yields (Scheme 4). 
Conclusions 
Two stereoisomers of octahydroindole-2-phosphonic acid 
exhibiting a cis ring fusion and differing in the stereochemistry at 
the  carbon have been synthesised for the first time. The 
procedure relies on the use of a common, inexpensive, 
commercially available precursor, which is transformed into the 
desired compounds following stereodivergent routes. Full 
stereochemical control is achieved in both cases by efficiently 
combining the appropriate chemical transformations in the 
convenient order. Thus, when the hydrogenation step is performed 
before the introduction of the phosphonate group, only the 
compound exhibiting a trans relative disposition between the 
phosphonate and cyclohexane moieties is obtained. Conversely, 
when the phosphonate functionality is introduced prior to the 
hydrogenation of the aromatic ring, the cis stereoisomer is obtained 
exclusively. Therefore, a simple change in the order in which the 
two key reaction steps are carried out has allowed the simple and 
effective transformation of a common starting substrate into any of 
the target amino acids, with full stereochemical control. The 
compounds isolated are analogues of phosphoproline and may be 
of use in the development of biologically relevant materials.  
Experimental Section 
General: All reagents were used as received from commercial suppliers 
without further purification. Thin-layer chromatography (TLC) was 
performed on Macherey-Nagel Polygram® SIL G/UV254 precoated silica gel 
polyester plates. The products were visualized by exposure to UV light 
(254 nm), iodine vapours or charring with cerium molybdate stain [aqueous 
solution of phosphomolybdic acid (2%), CeSO4.4H2O (1%) and H2SO4 
(6%)]. Column chromatography was performed using 60 M (0.04–0.063 
mm) silica gel from Macherey-Nagel. Melting points were determined on a 
Gallenkamp apparatus. IR spectra were registered on a Nicolet Avatar 360 
FTIR spectrophotometer; max is given for the main absorption bands. 
1H, 
13C and 31P NMR spectra were recorded on a Bruker AV-400 instrument at 
room temperature using the residual solvent signal as the internal standard; 
chemical shifts () are expressed in parts per million and coupling constants 
(J) in Hertz. High-resolution mass spectra were obtained on a Bruker 
Microtof-Q spectrometer. 
X-ray structures: Single crystals of 7 and 14 were obtained by slow 
evaporation from dichloromethane/hexanes solutions. The X-ray diffraction 
data were collected at 150 K on an Oxford Diffraction Xcalibur 
diffractometer provided with a Sapphire CCD detector, using graphite 
monochromated Mo K radiation ( = 0.71073 Å). The structures were 
solved by direct methods using SHELXS-97[16a] and refinement was 
performed using SHELXL-97[16b] by the full-matrix least-squares technique 
with anisotropic thermal factors for heavy atoms. Hydrogen atoms were 
located by calculation and affected by an isotropic thermal factor fixed to 
1.2 times the Ueq of the carrier atom (1.5 for the methyl protons). CCDC 
812002 (7) and 812003 (14) contains the supplementary crystallographic 
data for this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
Summary of crystallographic data for 7 (C15H28NO5P): monoclinic, space 
group P21/c; a = 16.0908(6) Å, b = 9.8211(4) Å, c = 11.1937(4) Å,  = 
91.996(3) º; Z = 4; dcalcd = 1.252 g.cm
–3; 16834 reflections collected, 3129 
unique (Rint = 0.0838); data/parameters: 3129/201; final R indices (I > 2I): 
R1 = 0.058, wR2 = 0.140; final R indices (all data): R1 = 0.111, wR2 = 0.154; 
goodness of fit: 0.918; highest residual electron density: 0.74 e Å–3. 
 5 
Summary of crystallographic data for 14 (C15H28NO5P): monoclinic, space 
group P21/c; a = 15.9271(7) Å, b = 9.7690(5) Å, c = 11.4281(5) Å,  = 
101.002(4) º; Z = 4; dcalcd = 1.269 g.cm
–3; 17919 reflections collected, 3416 
unique (Rint = 0.037); data/parameters: 3416/201; final R indices (I > 2I): 
R1 = 0.033, wR2 = 0.076; final R indices (all data): R1 = 0.052, wR2 = 0.080; 
goodness of fit: 0.968; highest residual electron density: 0.40 e Å–3. 
cis-Octahydroindol-2-one (2): A mixture of 2-indolinone (1.00 g, 7.51 
mmol) and PtO2 (100 mg) in acetic acid (50 mL) was heated at 70 ºC under 
an atmospheric pressure of hydrogen for 48 h. Filtration of the catalyst and 
evaporation of the solvent provided 2 as a colourless oil (1.04 g, 7.50 mmol, 
100% yield). IR (neat): v = 1692 cm–1. 1H NMR (400 MHz, CDCl3): δ = 
6.69 (bs, 1H, NH), 3.65 (q, J = 5.1 Hz, 1H, 7a-H), 2.36–2.25 (m, 2H, 3-H, 
3a-H), 2.05–1.95 (m, 1H, 3-H’), 1.68–1.54 (m, 3H, cyclohexane-CH2), 
1.53–1.20 (m, 5H, cyclohexane-CH2) ppm. 
13C NMR (100 MHz, CDCl3): δ 
= 179.09 (CO), 53.44 (7a-C), 38.15 (3-C), 34.44 (3a-C), 28.76 
(cyclohexane-CH2), 27.35 (cyclohexane-CH2), 22.80 (cyclohexane-CH2), 
20.66 (cyclohexane-CH2) ppm. HRMS (ESI): calcd. for C8H13NNaO 
[M+Na]+ 162.0889; found 162.0886.  
cis-N-(tert-Butoxycarbonyl)octahydroindol-2-one (3): A mixture of 2 
(262 mg, 1.88 mmol), 4-(dimethylamino)pyridine (23 mg, 0.19 mmol), and 
di-tert-butyl dicarbonate (1.03 g, 4.71 mmol) in THF (15 mL) was stirred at 
room temperature for 12 h.  Evaporation of the solvent followed by column 
chromatography (eluent: hexanes/ethyl acetate 4:1) afforded 3 as a white 
solid (344 mg, 1.44 mmol, 76% yield). M.p. 61–63 ºC. IR (KBr): v = 1785, 
1711 cm–1. 1H NMR (400 MHz, CDCl3): δ = 4.01–3.94 (m, 1H, 7a-H), 
2.54–2.41 (m, 2H, 3-H, 3a-H), 2.31–2.25 (m, 1H, 3-H’), 2.22–2.14 (m, 1H, 
cyclohexane-CH2), 1.76–1.44 (m, 4H, cyclohexane-CH2), overlapped with 
1.50 (s, 9H, tBu), 1.35–1.11 (m, 3H, cyclohexane-CH2) ppm. 
13C NMR 
(100 MHz, CDCl3): δ = 174.31 (CO), 150.06 (COO), 82.59 (tBu-C), 57.82 
(7a-C), 35.77 (3-C), 31.64 (3a-C), 28.17 (tBu-CH3), 28.15 (cyclohexane-
CH2), 25.94 (cyclohexane-CH2), 22.88 (cyclohexane-CH2), 20.37 
(cyclohexane-CH2) ppm. HRMS (ESI): calcd. for C13H21NNaO3 [M+Na]
+ 
262.1414; found 262.1418.  
Dimethyl (2S*,3aS*,7aS*)-N-(tert-butoxycarbonyl)octahydroindole-2-
phosphonate (7): A 1M solution of di-iso-butylaluminum hydride in 
hexanes (1.60 mL, 1.60 mmol) was slowly added to a solution of 3 (252 mg, 
1.05 mmol) in anhydrous THF (5 mL) kept at –78 ºC under argon. After 
stirring at this temperature for 2 h, the reaction was treated with saturated 
aqueous sodium acetate (3 mL) and allowed to warm to room temperature. 
A 3:1 mixture of diethyl ether and saturated aqueous ammonium chloride 
(16 mL) was then added and the resulting mixture was stirred at room 
temperature until a suspension was formed. The solid was filtered off under 
reduced pressure and washed with diethyl ether (2 x 10 mL). The organic 
layer was separated and the aqueous phase was extracted with diethyl ether 
(2 x 20 mL). The combined organic extracts were washed with water (20 
mL) and brine (20 mL), dried, filtered, and evaporated to provide the 
hemiaminal 4 as an oil. It was dissolved in methanol (5 mL) and treated 
with pyridinium p-toluenesulphonate (26 mg, 0.11 mmol). After stirring at 
room temperature for 2 h, triethylamine (48 mg, 0.07 mL, 0.47 mmol) was 
added. The solvent was evaporated and the crude methoxyaminal 5 thus 
obtained was dissolved in anhydrous dichloromethane (4 mL) and kept 
under argon. Trimethyl phosphite (131 mg, 0.12 mL, 1.05 mmol) was 
added and the resulting solution was cooled to –20 ºC. Boron trifluoride 
etherate (149 mg, 0.13 mL, 1.05 mmol) was added dropwise and the 
reaction mixture was slowly warmed to room temperature and stirred for 12 
h. After quenching with water (2 mL), the two layers were separated and 
the aqueous phase was extracted with dichloromethane (2 x 5 mL). The 
combined organic extracts were dried, filtered, and concentrated. 
Purification by column chromatography (eluent: ethyl acetate/hexanes 4:1) 
afforded 7 as a white solid (199 mg, 0.60 mmol, 57% yield). M.p. 63–65 ºC. 
IR (KBr): v = 1702, 1244, 1072, 1038 cm–1. 1H NMR (400 MHz, CDCl3): δ 
= (duplicate signals are observed for some protons; asterisks indicate those 
corresponding to the minor rotamer) 4.21–4.14 (m, 1H, 2-H), 4.13*–4.07* 
(m, 1H, 2-H), 3.73 (d, J = 10.5 Hz, 3H, OMe), 3.72 (d, J = 10.5 Hz, 3H, 
OMe), 3.70–3.62 (m, 1H, 7a-H), 2.77–2.66 (m, 1H, 3a-H), 2.61*–2.49* (m, 
1H, 3a-H), 2.41*–2.31* (m, 1H, 3-H), 2.30–2.10 (m, 2H, 3-H), 2.05–1.95 
(m, 1H, cyclohexane-CH2), 1.74–1.53 (m, 3H, cyclohexane-CH2), 1.49–
1.39 (m, 1H, cyclohexane-CH2) overlapped with 1.44 (s, 9H, tBu), 1.28–
0.92 (m, 3H, cyclohexane-CH2) ppm. 
13C NMR (100 MHz, CDCl3): δ = 
(duplicate signals are observed for most carbons; asterisks indicate those 
corresponding to the minor rotamer) 154.61 (COO), 80.07* (tBu-C), 79.75 
(tBu-C), 57.50 (7a-C), 57.11* (7a-C), 53.86* (d, J = 158.9 Hz, 2-C), 53.43* 
(d, J = 7.0 Hz, OMe), 52.79 (d, J = 160.5 Hz, 2-C), 52.61 (d, J = 7.1 Hz, 
OMe), 36.23 (3a-C), 35.60* (3a-C), 29.73* (3-C), 28.50 (tBu-CH3), 28.35* 
(tBu-CH3), 27.81 (3-C), 26.82* (cyclohexane-CH2), 26.01 (cyclohexane-
CH2), 23.97 (cyclohexane-CH2), 23.58* (cyclohexane-CH2), 21.02* 
(cyclohexane-CH2), 20.73 (cyclohexane-CH2) ppm. 
31P NMR (162 MHz, 
CDCl3): δ = (a duplicate signal is observed; an asterisk indicates that 
corresponding to the minor rotamer) 28.52*, 28.31 ppm. HRMS (ESI): 
calcd. for C15H28NNaO5P [M+Na]
+ 356.1597; found 356.1619. 
(2S*,3aS*,7aS*)-Octahydroindole-2-phosphonic acid hydrobromide 
(8): A 33% solution of hydrogen bromide in acetic acid (2 mL) was added 
to 7 (50 mg, 0.15 mmol) and the reaction mixture was stirred at room 
temperature for 2 h. The solvent was evaporated and the residue was taken 
up in water and lyophilised to afford 8 as a white solid (43 mg, 0.15 mmol, 
100% yield). M.p. 262–264 ºC (dec.). IR (KBr): v = 3411, 1153, 1079 cm–1. 
1H NMR (400 MHz, DMSO-d6): δ = 9.33–9.01 (m, 2H, NH2), 4.66 (bs, 2H, 
OH), 3.77–3.65 (m, 1H, 2-H), 3.54–3.45 (m, 1H, 7a-H), 2.31–2.21 (m, 1H, 
3a-H), 2.12–1.96 (m, 2H, 3-H), 1.74–1.42 (m, 5H, cyclohexane-CH2), 
1.39–1.18 (m, 3H, cyclohexane-CH2) ppm. 
13C NMR (100 MHz, DMSO-
d6): δ = 59.16 (d, J = 3.5 Hz, 7a-C), 51.50 (d, J = 150.0 Hz, 2-C), 36.43 (d, 
J = 4.9 Hz, 3a-C), 29.87 (3-C), 24.82 (cyclohexane-CH2), 23.58 
(cyclohexane-CH2), 21.36 (cyclohexane-CH2), 20.42 (cyclohexane-CH2) 
ppm. 31P NMR (162 MHz, DMSO-d6): δ = 16.11 ppm. HRMS (ESI): calcd. 
for C8H17NO3P [M–Br]
+ 206.0941; found 206.0944. 
Dimethyl (2S*,3aS*,7aS*)-octahydroindole-2-phosphonate (9): An ice-
cooled solution of 7 (43 mg, 0.13 mmol) in dichloromethane (2.6 mL) was 
treated with trifluoroacetic acid (148 mg, 0.10 mL, 1.30 mmol) and stirred 
at room temperature for 12 h. The reaction mixture was diluted with 
dichloromethane (10 mL) and saturated aqueous sodium hydrogencarbonate 
(5 mL) was added. The layers were separated and the aqueous phase was 
further extracted with dichloromethane (10 mL). The combined organic 
layers were washed with brine (10 mL), dried, and filtered. Evaporation of 
the solvent afforded 9 as a white solid (28 mg, 0.12 mmol, 91% yield). M.p. 
173–175 ºC (dec.). IR (KBr): v = 3428, 1236, 1045 cm–1. 1H NMR (400 
MHz, CDCl3): δ = 3.72 (d, J = 10.3 Hz, 3H, OMe), 3.71 (d, J = 10.2 Hz, 3H, 
OMe), 3.54 (ddd, J = 9.3, 7.8, 5.2, 1H, 2-H), 3.15–3.10 (m, 1H, 7a-H), 2.11 
(bs, 1H, NH), 2.03–1.91 (m, 2H, 3-H, 3a-H), 1.80–1.70 (m, 1H, 3-H’), 
1.61–1.39 (m, 4H, cyclohexane-CH2), 1.33–1.25 (m, 2H, cyclohexane-CH2), 
1.20–1.07 (m, 2H, cyclohexane-CH2) ppm. 
13C NMR (100 MHz, CDCl3): δ 
= 57.55 (d, J = 6.3 Hz, 7a-C), 53.11 (d, J = 7.1 Hz, OMe), 52.98 (d, J = 7.3 
Hz, OMe), 51.31 (d, J = 168.4 Hz, 2-C), 38.07 (d, J = 4.6 Hz, 3a-C), 32.22 
(3-C), 27.28 (cyclohexane-CH2), 26.65 (cyclohexane-CH2), 23.59 
(cyclohexane-CH2), 20.95 (cyclohexane-CH2) ppm. 
31P NMR (162 MHz, 
CDCl3): δ = 29.47 ppm. HRMS (ESI): calcd. for C10H21NO3P [M+H]
+ 
234.1254; found 234.1247.  
N-(tert-Butoxycarbonyl)-2-indolinone (10): A mixture of 2-indolinone 
(2.00 g, 15.04 mmol), di-tert-butyl dicarbonate (8.20 g, 37.59 mmol), and 
sodium carbonate (14.34 g, 135.32 mmol) in THF (60 mL) was heated at 70 
ºC for 12 h. The solid was filtered off and the solvent was evaporated. 
Purification by column chromatography (eluent: hexanes/ethyl acetate 9:1) 
afforded 10 as a white solid (2.72 g, 11.66 mmol, 78% yield). M.p. 63–66 
ºC. IR (KBr): v = 1788, 1720 cm–1. 1H NMR (400 MHz, CDCl3): δ = 7.78 
(d, J = 7.8, 1H, Ar), 7.32–7.27 (m, 1H, Ar), 7.26–7.22 (m, 1H, Ar), 7.13 (td, 
J = 7.8, 1.0 Hz, 1H, Ar), 3.65 (s, 2H, 3-H), 1.64 (s, 9H, tBu) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 173.24 (CO), 149.31 (COO), 141.11 (Ar), 
128.19 (Ar), 124.33 (Ar), 124.32 (Ar), 123.34 (Ar), 115.18 (Ar), 84.48 
(tBu-C), 36.68 (3-C), 28.23 (tBu-CH3) ppm. HRMS (ESI): calcd. for 
C13H15NNaO3 [M+Na]
+ 256.0944; found 256.0948.  
Dimethyl N-(tert-butoxycarbonyl)indoline-2-phosphonate (13): A 
solution of 10 (2.61 g, 11.20 mmol) in anhydrous THF (60 mL) under 
argon was cooled to –78 ºC. A 1M solution of lithium triethylborohydride in 
THF (16.80 mL, 16.80 mmol) was added dropwise and the reaction mixture 
was stirred at this temperature for 1 h.  It was treated with water (10 mL) 
and then allowed to warm to room temperature. Saturated aqueous sodium 
hydrogencarbonate (25 mL) was then added followed by 30% aqueous 
hydrogen peroxide (10 mL). The resulting mixture was stirred vigorously 
for 1 h and then extracted with ethyl acetate (2 x 20 mL). The organic 
extracts were washed with water (20 mL) and brine (20 mL), dried, and 
filtered. Evaporation of the solvent afforded the hemiaminal 11 as a yellow 
oil. The crude product was dissolved in anhydrous dichloromethane (40 
 6 
mL) and trimethyl phosphite (1.39 g, 1.32 mL, 11.20 mmol) was added at 
room temperature under an argon atmosphere. The solution was cooled to –
20 ºC and boron trifluoride etherate (1.59 g, 1.41 mL, 11.20 mmol) was 
added dropwise. The reaction mixture was slowly warmed to room 
temperature and stirred for 12 h. After quenching with water (10 mL), the 
two layers were separated and the aqueous phase was extracted with 
dichloromethane (2 x 20 mL). The combined organic extracts were dried, 
filtered, and concentrated. Purification by column chromatography (eluent: 
ethyl acetate/hexanes 4:1) gave 13 as an oil (1.09 g, 3.32 mmol, 30% yield). 
IR (neat): v = 1702, 1250, 1060, 1031 cm–1. 1H NMR (400 MHz, DMSO-
d6): δ = 7.54 (bs, 1H, Ar), 7.22 (d, J = 7.4 Hz, 1H, Ar), 7.16 (t, J = 7.7 Hz, 
1H, Ar), 6.96 (dt, J = 7.4, 1.0 Hz, 1H, Ar), 4.84 (ddd, J = 11.2, 4.3, 2.3 Hz, 
1H, 2-H), 3.61 (d, J = 10.5 Hz, 3H, OMe), 3.57–3.45 (m, 1H, 3-H) 
overlapped with 3.54 (d, J = 10.5 Hz, 3H, OMe), 3.22–3.08 (m, 1H, 3-H’), 
1.52 (s, 9H, tBu) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 151.38 (COO), 
141.72 (Ar), 130.45 (Ar), 127.20 (Ar), 124.58 (Ar), 122.90 (Ar), 115.24 
(Ar), 81.08 (tBu-C), 54.30 (d, J = 156.4 Hz, 2-C),  52.89 (d, J = 6.9 Hz, 
OMe), 52.74 (d, J = 6.5 Hz, OMe), 29.68 (3-C), 27.81 (tBu-CH3) ppm. 
31P 
NMR (162 MHz, DMSO-d6): δ = 25.82 ppm. HRMS (ESI): calcd. for 
C15H22NNaO5P [M+Na]
+ 350.1128; found 350.1123.  
Dimethyl (2R*,3aS*,7aS*)-N-(tert-butoxycarbonyl)octahydroindole-2-
phosphonate (14): A mixture of 13 (206 mg, 0.63 mmol) and PtO2 (21 mg) 
in acetic acid (10 mL) was heated at 45 ºC under an atmospheric pressure of 
hydrogen for 12 h. Filtration of the catalyst and evaporation of the solvent 
afforded 14 as a white solid (209 mg, 0.63 mmol, 100% yield). M.p. 72–74 
ºC. IR (KBr): v = 1693, 1230, 1034 cm–1. 1H NMR (400 MHz, DMSO-d6): 
δ = 4.08–4.01 (m, 1H, 2-H), 3.81–3.74 (m, 1H, 7a-H), 3.65 (d, J = 10.5 Hz, 
3H, OMe), 3.64 (d, J = 10.5 Hz, 3H, OMe), 2.20–1.98 (m, 3H, 3-H, 3a-H), 
1.72–1.53 (m, 4H, cyclohexane-CH2), 1.49–1.34 (m, 2H, cyclohexane-CH2) 
overlapped with 1.40 (s, 9H, tBu), 1.28–1.02 (m, 2H, cyclohexane-CH2) 
ppm. 13C NMR (100 MHz, DMSO-d6): δ = 153.81 (COO), 78.94 (tBu-C), 
58.35 (7a-C), 52.92 (d, J = 6.6 Hz, OMe), 52.18 (d, J = 5.7 Hz, OMe), 
52.00 (d, J = 163.9 Hz, 2-C), 35.87 (d, J = 5.9 Hz, 3a-C), 29.00 (3-C), 
27.96 (tBu-CH3), 27.32 (cyclohexane-CH2), 25.19 (cyclohexane-CH2), 
23.55 (cyclohexane-CH2), 19.85 (cyclohexane-CH2) ppm. 
31P NMR (162 
MHz, CDCl3): δ = 29.04 ppm. HRMS (ESI): calcd. for C15H28NNaO5P 
[M+Na]+ 356.1597; found 356.1599.   
(2R*,3aS*,7aS*)-Octahydroindole-2-phosphonic acid hydrobromide 
(15): A 33% solution of hydrogen bromide in acetic acid (2 mL) was added 
to 14 (50 mg, 0.15 mmol) and the reaction mixture was stirred at room 
temperature for 2 h. The solvent was evaporated and the residue was taken 
up in water and lyophilised to afford 15 as a white solid (43 mg, 0.15 mmol, 
100% yield). M.p. 138–140 ºC (dec.). IR (KBr): v = 3413, 1179, 1024 cm–1. 
1H NMR (400 MHz, DMSO-d6): δ = 9.62 (bs, 1H, NH), 8.68 (bs, 1H, NH), 
4.68 (bs, 2H, OH), 3.61–3.48 (m, 2H, 2-H, 7a-H), 2.32–2.22 (m, 1H, 3a-H), 
2.14–2.03 (m, 1H, 3-H), 2.02–1.91 (m, 1H, 3-H’), 1.84–1.74 (m, 1H, 
cyclohexane-CH2), 1.72–1.46 (m, 4H, cyclohexane-CH2), 1.41–1.16 (m, 3H, 
cyclohexane-CH2) ppm. 
13C NMR (100 MHz, DMSO-d6): δ = 58.62 (7a-C), 
53.07 (d, J = 147.8 Hz, 2-C), 36.56 (d, J = 8.2 Hz, 3a-C), 28.73 (3-C), 
24.70 (cyclohexane-CH2), 24.25 (cyclohexane-CH2), 22.05 (cyclohexane-
CH2), 20.22 (cyclohexane-CH2) ppm. 
31P NMR (162 MHz, DMSO-d6): δ = 
14.66 ppm. HRMS (ESI): calcd. for C8H17NO3P [M–Br]
+ 206.0941; found 
206.0936.  
Dimethyl (2R*,3aS*,7aS*)-octahydroindole-2-phosphonate (16). An ice-
cooled solution of 14 (64 mg, 0.19 mmol) in dichloromethane (3.8 mL) was 
treated with trifluoroacetic acid (219 mg, 0.15 mL, 1.92 mmol) and stirred 
at room temperature for 12 h. The reaction mixture was diluted with 
dichloromethane (15 mL) and saturated aqueous NaHCO3 (8 mL) was 
added. The layers were separated and the aqueous phase was further 
extracted with dichloromethane (15 mL). The combined organic layers 
were washed with brine (10 mL), dried, and filtered. Evaporation of the 
solvent provided 16 as a white solid (42 mg, 0.18 mmol, 93% yield). M.p. 
123–125 ºC (dec.). IR (KBr): v = 3391, 1230, 1198, 1041 cm–1. 1H NMR 
(400 MHz, CDCl3): δ = 3.79 (d, J = 10.3 Hz, 3H, OMe), 3.77 (d, J = 10.4 
Hz, 3H, OMe), 3.41 (ddd, J = 9.2, 8.4, 5.7 Hz, 1H, 2-H), 3.08–3.03 (m, 1H, 
7a-H), 2.24 (bs, 1H, NH), 2.07–197 (m, 2H, 3-H, 3a-H), 1.83–1.71 (m, 1H, 
3-H’), 1.68–1.55 (m, 2H, cyclohexane-CH2), 1.53–1.42 (m, 4H, 
cyclohexane-CH2), 1.34–1.17 (m, 2H, cyclohexane-CH2) ppm. 
13C NMR 
(100 MHz, CDCl3): δ = 58.60 (d, J = 13.1 Hz, 7a-C), 52.67 (d, J = 164.5 Hz, 
2-C), 53.41 (d, J = 6.8 Hz, OMe), 52.98 (d, J = 7.2 Hz, OMe), 38.26 (d, J = 
7.7 Hz, 3a-C), 32.05 (d, J = 1.9 Hz, 3-C), 28.70 (cyclohexane-CH2), 27.77 
(cyclohexane-CH2), 23.68 (cyclohexane-CH2), 21.91 (cyclohexane-CH2) 
ppm. 31P NMR (162 MHz, CDCl3): δ = 31.05 ppm. HRMS (ESI): calcd. for 
C10H21NO3P [M+H]
+ 234.1254; found 234.1253. 
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